By Ben Glickman

MorphoSys said its study of a treatment for myelofibrosis, a rare form of blood cancer, reached its primary endpoint, clearing the way for a new drug application in mid-2024.

The German pharmaceutical company said Monday its Phase 3 trial of pelabresib in combination with ruxolitinib in myelofibrosis patients found a statistically significant and clinically meaningful improvement in the portion of patients with a 35% or greater reduction in spleen volume after 24 weeks.

There was also a meaningful reduction in myelofibrosis symptoms, a key secondary endpoint, according to the company.

MorphoSys now intends to submit a new drug application for pelabresib in combination with ruxolitinib to U.S. and European regulators in mid-2024.

The company's combination therapy received fast track designation from the Food and Drug Administration in treating myelofibrosis in 2018.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

November 20, 2023 17:04 ET (22:04 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Morphosys (TG:MOR)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Morphosys.
Morphosys (TG:MOR)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Morphosys.